Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis
Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis
Zhang et al., 2025 | Medicine (Baltimore) | Meta Analysis
Citation
Zhang Heng, Yang Yunkai, ... Liu Zhelong. Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis. Medicine (Baltimore). 2025-Aug-29;104(35):e44043. doi:10.1097/MD.0000000000044043
Abstract
BACKGROUND: To assess the clinical benefits of Selenium (Se) supplementation in patients with Hashimoto thyroiditis (HT). METHODS: Eight databases were searched for randomized controlled trials. The outcomes of interest were thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TgAb), thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4). The study protocol is registered on INPLASY, DOI number is 10.37766/inplasy2022.10.0085. RESULTS: Twenty-one studies with a total of 1610 subjects were included. Serum TPOAb was significantly reduced after Se supplementation after 3 months (standardized mean difference [SMD] = -0.46, 95% confidence interval [CI]: -0.74 to -0.18, P = .001) and 6 months (SMD = -0.80, 95%CI: -1.38 to -0.21, P = .008). The serum TgAb levels decreased at 3 months (SMD = -0.46, 95%CI: -0.79 to -0.12, P = .007) but not at 6 months. Significant effects on declining the TSH titers were found after 6 months (SMD = -0.18, 95%CI = -0.35 to -0.01; P = .03). CONCLUSION: Se supplementation help reduce TPOAb and TSH levels in HT patients, leading to improvements in well-being or mood. Selenomethionine is more effective than NaSe and Se-yeast in the teatment of Hashimoto thyroid.
Key Findings
Twenty-one studies with a total of 1610 subjects were included. Serum TPOAb was significantly reduced after Se supplementation after 3 months (standardized mean difference [SMD] = -0.46, 95% confidence interval [CI]: -0.74 to -0.18, P = .001) and 6 months (SMD = -0.80, 95%CI: -1.38 to -0.21, P = .008). The serum TgAb levels decreased at 3 months (SMD = -0.46, 95%CI: -0.79 to -0.12, P = .007) but not at 6 months. Significant effects on declining the TSH titers were found after 6 months (SMD = -0.
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | hashimoto thyroiditis |
| Sample Size | 1610 |
| Age Range | See abstract |
| Condition | mood |
MeSH Terms
- Humans
- Hashimoto Disease
- Selenium
- Dietary Supplements
- Thyrotropin
- Randomized Controlled Trials as Topic
- Thyroxine
- Autoantibodies
- Treatment Outcome
- Triiodothyronine
- Iodide Peroxidase
Evidence Classification
- Level: Meta Analysis
- Publication Types: Journal Article, Systematic Review, Meta-Analysis
- Vertical: selenium-thyroid
Provenance
- PMID: 40898469
- DOI: 10.1097/MD.0000000000044043
- PMCID: PMC12401265
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09